MAGEA3 and head and neck squamous cell carcinoma: Additionally, MAGE-A3/A4 expression was positive in 39% of primary tumors, 42% of lymph node metastases, and 37% of tumor recurrences when observing MAGE-A3/A4 expression in patients with head and neck squamous cell carcinoma (15).